Obesity Clinical Trial
Official title:
Evaluation of GH/IGF-I Axis and of Replacement GH Therapy After Bariatric Surgery in Patients With Very Severe Obesity: Relationships With Body Composition
Obesity and obesity-related diseases have reached epidemic proportions in Western countries (1-3). Laparoscopic-adjustable silicone gastric banding (LASGB) is a purely restrictive operation that determine effective weight loss without inducing malabsorption (4-6). However, also after LASGB body weight loss is almost invariably associated with Free Fat Mass (FFM) loss, and the relevance of the FFM contribution to total energy expenditure is well-known (7-8). Different endocrine axes are reported to affect FFM. We previously reported that low levels of DHEA-S, an adrenal steroid with controversial anti-adipogenic and anti-atherogenic effects, are increased after the massive and sustainable weight loss induced by LASGB in severely obese premenopausal women and correlated with the higher post-operative FFM (9-10). It is also well known that GH/IGF-I axis exerts relevant effects on FFM and that reduced GH levels might increase Fat Mass (FM) and reduce FFM (11,12). Morbidly obese patients have a reduced GH secretion, generally reversible after weight loss (13-14). In a recent study currently in press, we reported that a persistent deficiency in the GH/IGF-I axis in very obese females is associated to lower decrease in FM after LASGB. Low IGF-I plasma levels have also been reported to be independent prognostic factors of liver steatosis and non-alcoholic steatohepatitis in morbidly obese patients (15) and ultrasound- measured hepatic left lobe volume might represent a reliable tool for the evaluation of liver involvement in obesity (16). GH deficiency (GHD) in adult patients is associated with an increase in FM and a parallel decrease in FFM (17). The severity of GDH is correlated to cardiovascular risk, body composition abnormalities and bone loss, and decreased left ventricular ejection fraction (18-20). GH therapy has been demonstrated to be effective in normalizing body composition, with beneficial effects up to a 2-years follow-up period (21-24). GH therapy has also been reported to be effective in sparing FFM during weight loss in obese patients and metabolic syndrome (25,26). However, these studies have some limitations due to the duration of the treatment and the lack of a preliminary evaluation of the GH/IGF-I axis secretory status in obese patients before the GH therapy. At present there are no data on the evaluation of the GH/IGF-I status before and after bariatric surgery and the effectiveness of recombinant GH treatment in very severe obese patients.
The objectives of the study are:
1. To evaluate the GH/GF-I status is correlation with body composition in very severe
obese patients. IGF-I levels were classified as deficient when the standard deviation
score from the mean was <-2 for age and gender.
2. To evaluate the efficacy of a medical treatment with recombinant GH replacement therapy
in very severe obese patients after LASGB on the Fat mass (%), free fat mass (%),
percent decrease of fat mass. In line with GHD diagnosis, obese patients with
persistent GHD after bariatric surgery will be randomized to be treated with or without
recombinant GH therapy with replacement doses, in addition to the controlled trial of
dietary management, as routinely performed after LASGB.
Study protocol The study protocol includes two different arms: a correlation observational
longitudinal open study (Phase I), and a treatment study (Phase II).
PHASE I: In the correlation study a clinical, biochemical and instrumental evaluation will
be performed in 20-30 patients with very severe obesity (grade III) with GHD followed-up in
a multi-disciplinary approach at the Unit of Endocrinology of the Departments of Molecular
and Clinical Endocrinology and Oncology and at the Physiology Nutrition Unit of the
Department of Neuroscience and the Department of Surgery of "S. Giovanni Bosco" Hospital of
Naples, according to the current criteria of the National Institute of Health (27). The
clinical examination will focus on the GH/IGF-I status effects on body composition changes
before and after LASGB. The clinical examination will determine anthropometric indexes
(weight, height, BMI, waist circumference). The biochemical evaluation will include the
measurement of lipid profile, fasting plasma glucose and insulin, liver test function, FT3,
FT4, GHRH + Arginine test to detect GHD, plasma IGF-I levels. The instrumental evaluation
will include DEXA Total Body and bioimpedance analysis to determine body composition, and
liver ultrasounds.
PHASE II: In the medical treatment protocol very severe obese patients with persistent GHD
after LASGB will be inclosed. Starting from 15-day, GHD patients were re-evaluated by GHRH +
Arginine test. After evaluation, the patients with persistent GHD will be randomized to be
treated with Recombinant GH replacement therapy (Group A: Recombinant GH replacement therapy
at the initial dose 0.15-0.30 mg/die; dose adjustment will be made according to IGF-I
levels; Group B: no GH treatment). In both subgroups, the diet will arranged to fit an
energy intake of 5.7 MJ/day (55% carbohydrate, 25% fat, 20% protein, 30 g fiber) and a
moderate-intensity activity (brisk walking for 30-45 min/day) will be encouraged.
The evaluation of medical treatment efficacy will be based on the analysis of changes in
anthropometric indexes, IGF-I levels, liver function test, body composition assessed by DEXA
Total Body and bioimpedance analysis, liver ultrasounds. At 3 and 6 months, the patients of
both subgroups A and B will be clinically re-evaluated, plasma samples for metabolic, liver
function tests, and endocrine profile will be obtained, body composition and liver
ultrasounds will be determined. At the end of the 6-months period of treatment and
observation, the GH response to a subsequent GHRH + Arginine will be re-tested to confirm or
to exclude GHD. All the patients with persistent GHD will continue recombinant GH therapy.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |